Guide

Registered direct offering explained

Harbor MedTech needed $92 million in February 2026 to fund a pivotal trial enrollment push. The CFO had two weeks of cash runway at current burn and a volatile small-cap chart — a full overnight follow-on roadshow risked leaking the deal and widening the discount. Instead, management filed a prospectus supplement under its existing Form S-3 shelf, engaged a placement agent, and priced a registered direct offering (RDO) to a handful of institutional accounts in a single session: 8.2 million shares at $11.22, a 4.8% discount to the prior close, plus warrants exercisable at $13.50. Cash hit the balance sheet before the next market open. Retail holders saw the 8-K the same evening and sold into the print, not realizing the warrants added another 6.4% of potential dilution on a treasury-stock-method basis.

An RDO is a primary equity sale where newly issued shares are registered on a shelf and placed directly with qualified buyers — typically mutual funds, hedge funds, and family offices — without a broad underwritten roadshow. It sits between a marketed follow-on and a negotiated PIPE in speed, disclosure, and discount. This guide explains shelf mechanics, placement-agent economics, pricing and warrant structures, dilution math, the Harbor MedTech walkthrough, a decision table vs other raise vehicles, common pitfalls, and an issuer and investor checklist.

What a registered direct offering is

A registered direct offering sells newly issued common stock (or pre-funded warrants in lieu of shares) that is already covered by an effective SEC registration statement — almost always a Form S-3 shelf for seasoned issuers. Buyers receive freely tradable registered shares at closing; there is no separate resale registration period like many unregistered PIPEs.

Key traits that distinguish RDOs from other raises:

Placement-led, not broadly marketed — a placement agent or financial advisor soundings a targeted investor list rather than running a multi-day bookbuild with a syndicate of underwriters.
Compressed timeline — announce, price, and close often within one trading session or overnight, minimizing information leakage.
Modest size band — common in the $25–$150 million range for small and mid caps; mega-caps rarely use RDOs for large raises.
Primary proceeds only — unlike mixed follow-ons, RDOs almost always issue new company shares; insiders do not sell into the deal.

Investors sometimes lump RDOs with PIPEs because both involve negotiated placements. The legal difference matters: RDO shares are registered at closing; classic PIPEs may issue unregistered securities first and register them later via a resale S-1, creating a supply overhang until effectiveness.

Shelf registration and the prospectus supplement

Eligibility for Form S-3 requires public reporting history, timely filings, and sufficient public float. The company files a shelf registration registering a dollar pool (e.g. $300 million of common stock) valid for three years. When it wants to raise, it files a short prospectus supplement on EDGAR with:

Number of shares (or maximum dollar amount) offered
Stated use of proceeds
Placement agent identity and compensation (often 3–6% of gross)
Whether warrants or pre-funded warrants are attached

Because the base shelf is already effective, the supplement can go live quickly after board approval. Legal teams still run a 10b-5 diligence process on material disclosures before signing. Missing a quarterly 10-Q or letting the shelf lapse forces a slower S-1, which defeats the RDO’s main advantage: speed.

Pricing, discounts, and warrant coverage

Discount to unaffected price

RDO buyers accept a pricing discount to the last sale or volume-weighted average price (VWAP) because they provide same-day liquidity and absorb supply without a broad auction. Discounts typically run 3–7% for liquid mid caps and can exceed 10% for volatile micro caps or deals with warrant sweeteners.

Warrants and pre-funded warrants

Placement agents often attach warrants exercisable above the offer price (e.g. 100% coverage at a 25–50% premium to the deal price) or issue pre-funded warrants (nominal $0.001 exercise) when buyers want equity exposure without crossing ownership-reporting thresholds. Warrants add potential dilution; model them with the treasury stock method alongside basic and fully diluted share count. See equity warrant coverage for reset clauses that can widen dilution if the stock falls post-deal.

Dilution math

If Harbor MedTech had 95 million shares outstanding before the RDO and issued 8.2 million new shares, primary dilution is 8.2 / 103.2 ≈ 7.9%. If warrants with 100% coverage at $13.50 are in-the-money later, fully diluted count rises further. Compare pro forma cash per share: $92M raised minus 5% fees ≈ $87.4M net; if pre-deal enterprise value was $1.1B, the question is whether trial success probability times peak sales justifies the ownership slice sold — not whether the discount alone looked “cheap.”

RDO vs overnight follow-on vs PIPE vs ATM

Vehicle	Speed	Typical discount	Registration at close	Best when
Registered direct (RDO)	Same day / overnight	3–7% (+ warrants)	Yes — shelf supplement	Urgent primary capital; limited leak window; S-3 eligible
Overnight marketed follow-on	1–2 days	4–8%	Yes	Larger size; broader institutional book; lead underwriter syndicate
PIPE (unregistered)	Days to weeks	10–20%+	Often delayed resale S-1	Not S-3 eligible; distressed balance sheet; deep discount tolerance
ATM program	Weeks to months	Near market (agent spread)	Yes — dribble off shelf	No urgent lump sum; minimize headline shock
Rights offering	Weeks	Subscription discount to ex-rights	Yes	Existing holder participation; fair access priority

Harbor MedTech walkthrough

Situation: Phase 3 enrollment behind schedule; $18M quarterly burn; $24M cash. Debt covenant blocked additional borrowing without equity cure.

Structure: $92M gross RDO off $250M shelf; 8.2M shares + 8.2M warrants at $13.50; 5% placement fee; no insider participation.

Market reaction: Stock closed $11.78; deal priced $11.22 (−4.8%). Next-day open $10.95 on combined discount print and warrant overhang fears. By day five, shares recovered to $11.40 as enrollment data readout approached — but fully diluted models that ignored warrants overstated near-term EPS by $0.06.

Lessons: RDO speed preserved the trial timeline; warrant dilution belonged in the board deck day one; placement size relative to 30-day average volume (1.4×) explained the two-day volume spike better than “fundamentals changed.”

Common pitfalls

Shelf not ready — expired S-3 or missing 10-K forces a slow S-1 when speed was the whole point.
Warrant dilution omitted — 100% coverage at modest premiums still moves fully diluted EPS; disclose in the supplement summary.
Stacking with ATM dribble — RDO plus undisclosed ATM sales reads as double-dipping; coordinate disclosure.
Charter share limits — authorized but unissued shares below deal size triggers a shareholder vote delay.
Material nonpublic information — pricing while sitting on undisclosed trial data invites 10b-5 exposure; pause or disclose.
Index float neglect — 8% share-count jump can shift index band and passive flows for a week post-close.
Confusing RDO with secondary blocks — RDOs are primary; insider sales use different structures and optics.
Discount-only analysis — a 4% discount on bad capital deployment still destroys value; compare ROI on proceeds vs ownership sold.

Issuer and investor checklist

Confirm S-3 shelf effective with enough remaining capacity for deal + warrants.
Verify authorized share count and board approvals before signing placement agreement.
Run 10b-5 diligence; align timing with earnings blackouts and trial readouts.
Model basic and fully diluted share count including warrant treasury method.
Disclose use of proceeds, fees, and warrant terms in IR release and 8-K.
Benchmark discount and warrant coverage to peer RDOs of similar size and volatility.
Coordinate with placement agent on investor list concentration and 13F visibility.
Update cash runway and burn guidance in the same disclosure package.
Post-deal: monitor volume, short interest, and passive index rebalance windows.
Investors: read prospectus supplement, not only the headline discount percentage.

Key takeaways

RDOs sell registered primary shares off a shelf directly to institutions — fast, but not free.
Discounts and warrant coverage compensate buyers for same-day absorption of new supply.
Registered at close beats unregistered PIPE resale lag when S-3 eligibility exists.
Harbor MedTech funded its trial in one session; warrant dilution still mattered for EPS models.
Choose RDOs for urgent, modest primary raises; use marketed follow-ons for maximum size and book depth.